Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pyrotinib Plus Fulvestrant in Patients HR+/HER2+ Metastatic Breast Cancer : a Prospective, Single-arm, Single-center Study

NCT04033172 is registered in ClinicalTrials.gov with Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT04033172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04033172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pyrotinib Plus Fulvestrant in Patients HR+/HER2+ Metastatic Breast Cancer : a Prospective, Single-arm, Single-center Study
Lead sponsor
Chinese Academy of Medical Sciences
Phase
Phase 2
Overall status
Unknown status
Start date
November 1, 2018
Completion date
September 1, 2021
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2-positive breast cancer